Ngm Biopharmaceuticals Stock Revenue

NGM Biopharmaceuticals fundamentals help investors to digest information that contributes to NGM Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of NGM Stock. The fundamental analysis module provides a way to measure NGM Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NGM Biopharmaceutica stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NGM Biopharmaceuticals Company Revenue Analysis

NGM Biopharmaceutica's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current NGM Biopharmaceutica Revenue

    
  4.42 M  
Most of NGM Biopharmaceutica's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NGM Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, NGM Biopharmaceuticals reported 4.42 M of revenue. This is 99.94% lower than that of the Pharmaceuticals sector and 99.41% lower than that of the Health Care industry. The revenue for all United States stocks is 99.95% higher than that of the company.

NGM Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NGM Biopharmaceutica's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NGM Biopharmaceutica could also be used in its relative valuation, which is a method of valuing NGM Biopharmaceutica by comparing valuation metrics of similar companies.
NGM Biopharmaceutica is currently under evaluation in revenue category among its peers.

NGM Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Consideration for investing in NGM Stock

If you are still planning to invest in NGM Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NGM Biopharmaceutica's history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stocks Directory
Find actively traded stocks across global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.